Search Videos and More
ASCO 2026 pancreatic cancer updates
Chao Family Comprehensive Cancer Center Director discusses results from the phase 3 RASolute 302 trial of daraxonrasib.STOPGAP II — a national randomized clinical trial for patients with stage 4 gastric cancer
What starts at UCI Health can help shape the national conversation.The importance of robust genomic testing for patients
Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.Renowned medical oncologist shares key takeaways from ASCO 2026
Farshid Dayyani, MD, PhD shared his key takeaways on emerging developments in gastrointestinal oncology at ASCO 2026.Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma
UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.Promising early results for a new treatment in head and neck cancer
Victoria Villaflor, MD shared promising early results at ASCO 2026 for a new treatment approach in head and neck cancer.Promising phase 1 data presented by UCI Health radiologist at ASCO 2026
Nadine Abi-Jaoudeh, MD shared promising Phase 1 data at ASCO 2026 regarding a novel interventional approach for locally advanced pancreatic cancer.UCI Health is at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.UCI Health Chao Family Comprehensive Cancer Center Annual Report 2025
At the UCI Health Chao Family Comprehensive Cancer Center, we have made unparalleled progress in our efforts to prevent, treat and cure cancer, ensuring that the people of Orange County and beyond live longer and healthier lives.New data, recurring questions
Where do noncovalent BTK inhibitors fit in chronic lymphocytic leukemia (CLL) care?Refining Conditioning Intensity for Older Adults Undergoing Transplant
New data presented at ASH 2025 highlight how age, physiologic reserve and toxicity risk should guide conditioning intensity in older patients undergoing transplant.Rethinking the Biology of Chronic Myeloid Leukemia
New research from UC Irvine challenges a long-standing assumption in chronic myeloid leukemia